Distribution of Serotypes, Vaccine Coverage, and Antimicrobial Susceptibility Pattern of Streptococcus Pneumoniae in Children Living in SAARC Countries: A Systematic Review

Abstract

IntroductionEach SAARC nation falls in the zone of high incidence of pneumococcal disease but there is a paucity of literature estimating the burden of pneumococcal disease in this region.ObjectiveTo identify the prevalent serotypes causing invasive pneumococcal disease in children of SAARC countries, to determine the coverage of these serotypes by the available vaccines, and to determine the antibiotic resistance pattern of Streptococcus pneumoniae.MethodsWe searched major electronic databases using a comprehensive search strategy, and additionally searched the bibliography of the included studies and retrieved articles till July 2014. Both community and hospital based observational studies which included children aged ≤12 years as/or part of the studied population in SAARC countries were included.ResultsA total of 17 studies were included in the final analysis. The period of surveillance varied from 12–96 months (median, 24 months). The most common serotypes country-wise were as follows: serotype 1 in Nepal; serotype 14 in Bangladesh and India; serotype 19F in Sri Lanka and Pakistan. PCV-10 was found to be suitable for countries like India, Nepal, Bangladesh, and Sri Lanka, whereas PCV-13 may be more suitable for Pakistan. An increasing trend of non-susceptibility to antibiotics was noted for co-trimoxazole, erythromycin and chloramphenicol, whereas an increasing trend of susceptibility was noted for penicillin.ConclusionDue to paucity of recent data in majority of the SAARC countries, urgent large size prospective studies are needed to formulate recommendations for specific pneumococcal vaccine introduction and usage of antimicrobial agents in these regions.

Improving vaccines against Streptococcus pneumoniae using synthetic glycans

“…Serotype replacement, the observation that infection is caused by serotypes not included in marketed vaccines, has been widely reported (30). S. pneumoniae serotypes that are not included in current marketed vaccines such as ST2 and ST8 are responsible for IPDs in risk groups globally (31)(32)(33). Coformulation of licensed polysaccharide conjugate vaccines and oligosaccharide-based glycoconjugate vaccine candidates of nonvaccine serotypes would increase serotype coverage.…”

Streptococcus pneumoniae serotype prevalence and antibiotic resistance among young children with invasive pneumococcal disease: experience from a tertiary care center in South India

“…[2][3][4] A systematic review has revealed that only 7 serogroups (1, 5, 6A, 6B, 14, 19F, 23F) are the most common globally in the pediatric age group. 5 Studies have demonstrated that vaccination of children under 2 years of age can reduce the incidence of invasive pneumococcal disease. 6 In India, commonly prevalent serotypes are 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9A, 9N, 9V, 10A, 12F, 14, 15B, 18C, 19A, 19F and 23F, with serotypes 1 and 5 accounting for 30% of invasive pneumococcal disease (IPD) among the non-vaccinated population.…”

Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam: a dynamic transmission model

“…We explored the possible impact of introducing PCV13 with and without a catch-up campaign in Vietnam through a dynamic transmission model. Our results feed into current debates about introduction strategies, particularly in South-East Asia where pneumococcal disease burden is high [28], where many countries have not yet introduced PCV [5], and where epidemiological data to guide decision making remain scarce [28, 29]. Although Vietnam is Gavi-eligible and is expected to introduce PCV in the coming years, it has not yet applied [5].…”